Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Mast Cell Chymase Limits The Cardiac Efficacy Of Ang I-converting Enzyme Inhibitor Therapy In Rodents.
Chih-Chang Wei, N. Hase, Y. Inoue, Eddie W. Bradley, E. Yahiro, Ming Li, N. Naqvi, P. Powell, K. Shi, Y. Takahashi, K. Saku, H. Urata, L. Dell'Italia, A. Husain
Published 2010 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Ang I-converting enzyme (ACE) inhibitors are widely believed to suppress the deleterious cardiac effects of Ang II by inhibiting locally generated Ang II. However, the recent demonstration that chymase, an Ang II-forming enzyme stored in mast cell granules, is present in the heart has added uncertainty to this view. As discussed here, using microdialysis probes tethered to the heart of conscious mice, we have shown that chronic ACE inhibitor treatment did not suppress Ang II levels in the LV interstitial fluid (ISF) despite marked inhibition of ACE. However, chronic ACE inhibition caused a marked bradykinin/B2 receptor-mediated increase in LV ISF chymase activity that was not observed in mast cell-deficient KitW/KitW-v mice. In chronic ACE inhibitor-treated mast cell-sufficient littermates, chymase inhibition decreased LV ISF Ang II levels substantially, indicating the importance of mast cell chymase in regulating cardiac Ang II levels. Chymase-dependent processing of other regulatory peptides also promotes inflammation and tissue remodeling. We found that combined chymase and ACE inhibition, relative to ACE inhibition alone, improved LV function, decreased adverse cardiac remodeling, and improved survival after myocardial infarction in hamsters. These results suggest that chymase inhibitors could be a useful addition to ACE inhibitor therapy in the treatment of heart failure.
This paper references
Rodent alpha-chymases are elastase-like proteases.
Y. Kunori (2002)
Rodent α‐chymases are elastase‐like proteases
Y. Kunori (2002)
Peptidyl dipeptidase A: angiotensin I-converting enzyme.
P. Corvol (1995)
Chymase Inhibitor Improves Survival in Hamsters with Myocardial Infarction
F. Hoshino (2003)
Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
M. Azizi (1995)
A despecialization step underlying evolution of a family of serine proteases.
M. A. Wouters (2003)
Left ventricular remodeling after acute myocardial infarction.
M. Pfeffer (1995)
Structural Basis for Elastolytic Substrate Specificity in Rodent α-Chymases*
J. Kervinen (2008)
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
S. Yusuf (1991)
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
S. Yusuf (1992)
Mast cell tryptases and chymases in inflammation and host defense
G. Caughey (2007)
Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon.
B. Hoit (1995)
Is Angiotensin II a Direct Mediator of Left Ventricular Hypertrophy?: Time for Another Look
T. Reudelhuber (2007)
Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats.
J. Ménard (1997)
Recycling of mast cells following degranulation in vitro: an ultrastructural study.
S. Burwen (1982)
Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.
H. Urata (1993)
High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes.
V. Singh (2007)
Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression.
A. Everett (1994)
Angiotensins and the failing heart. Enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril.
H. Hirakata (1990)
Structural basis for elastolytic substrate specificity in rodent alpha-chymases.
J. Kervinen (2008)
A simple method for purification of chymase from rat tongue and rat peritoneal cells.
H. Kido (1984)
Suppressive effect of distinct bradykinin B2 receptor antagonist on allergen‐evoked exudation and leukocyte infiltration in sensitized rats
C. Bandeira‐Melo (1999)
Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases.
L. Dell'Italia (2002)
Angiotensin II-forming pathways in normal and failing human hearts.
H. Urata (1990)
Angiotensin II generation by mast cell alpha- and beta-chymases.
G. Caughey (2000)
c-kit Is Required for Cardiomyocyte Terminal Differentiation
M. Li (2008)
Possible roles of cardiac chymase after myocardial infarction in hamster hearts.
D. Jin (2001)
Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload.
T. Senbonmatsu (2000)
Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces.
L. Dell'Italia (1997)
Angiotensin II receptors.
R. Ardaillou (1999)
Use of a Biological Peptide Pump to Study Chronic Peptide Hormone Action in Transgenic Mice
J. P. van Kats (2001)
Angiotensin II Type 2 Receptor Stimulation: A Novel Option of Therapeutic Interference With the Renin-Angiotensin System in Myocardial Infarction?
E. Kaschina (2008)
Potential mechanism for bradykinin-activated and inositol tetrakisphosphate-dependent Ca2+ influx by Ras and GAP1 in fibroblast cells.
Haruhiro Higashida (1999)
A novel vascular smooth muscle chymase is upregulated in hypertensive rats.
C. Guo (2001)
Measurement of angiotensin I converting enzyme inhibition in the heart.
A. Kinoshita (1993)
Inotropic effects of angiotensin II on human cardiac muscle in vitro.
C. Moravec (1990)
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
W. Catterall (2003)
Involvement of chymase-mediated angiotensin II generation in blood pressure regulation.
Ming Li (2004)
Antihypertensive Therapy with MK 4211: Angiotensin II‐Renin Relationships to Evaluate Efficacy of Converting Enzyme Blockade
J. Biollaz (1982)
Formation of bradykinin: a major contributor to the innate inflammatory response.
K. Joseph (2005)
Cardiac interstitial bradykinin and mast cells modulate pattern of LV remodeling in volume overload in rats.
Chih-Chang Wei (2003)
Post acute myocardial infarction: the Fosinopril in Acute Myocardial Infarction Study (FAMIS).
C. Borghi (1997)
Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid. Inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by Ang-(1-9) formed by heart carboxypeptidase A-like activity.
J. Kokkonen (1997)
A small region in the angiotensin-converting enzyme distal ectodomain is required for cleavage-secretion of the protein at the plasma membrane.
S. Chattopadhyay (2008)
Effect of Reduced Angiotensin-Converting Enzyme Gene Expression and Angiotensin-Converting Enzyme Inhibition on Angiotensin and Bradykinin Peptide Levels in Mice
D. Campbell (2004)
82 – Peptidyl-dipeptidase A/angiotensin I-converting enzyme
P. Corvol (2004)
Species Differences in Angiotensin II Generation and Degradation by Mast Cell Chymases
Y. Kunori (2005)
Mast cells: a unique source of renin.
R. Silver (2004)
Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases.
C. Reilly (1982)
Angiotensin II generation by mast cell α- and β-chymases
G. Caughey (2000)
Plasma Angiotensins and Blood Pressure During Converting Enzyme Inhibition
P. Mento (1987)
International union of pharmacology. XXIII. The angiotensin II receptors.
M. de Gasparo (2000)
Differences in tissue angiotensin II-forming pathways by species and organs in vitro.
M. Akasu (1998)
The role of intracellular Ca2+ in the degranulation of skinned mast cells
K. Tasaka (2005)
Genetically mast-cell-deficient W/Wv and Sl/Sld mice. Their value for the analysis of the roles of mast cells in biologic responses in vivo.
S. Galli (1987)
Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart.
H. Urata (1990)
Handbook of proteolytic enzymes
A. Barrett (1998)
This paper is referenced by
Structure based inhibitor design studies on angiotensin converting enzyme homologues
C. Harrison (2015)
Role of Chymase in Matrix and Myocardial Remodeling Due to Mitral Regurgitation: Implications for Therapy
S. Melby (2013)
Clinical Applications of Renin-Angiotensin System Inhibitors
M. Burnier (2011)
Safety and efficacy of Qishen granules in patients with chronic heart failure: study protocol for a randomized controlled trial
J. Wang (2017)
All because of the mast cell: blocking the angiotensin receptor-1 should be better than inhibiting ACE (theoretically).
B. Becker (2011)
eview enin angiotensin aldosterone inhibition in the treatment of ardiovascular disease
M. Ferrarioa (2017)
The year in heart failure.
A. Owens (2012)
Renin-Angiotensin-Aldosterone System in Heart Failure: Focus on Nonclassical Angiotensin Pathways as Novel Upstream Targets Regulating Aldosterone
U. Tyrankiewicz (2019)
Proteases as Clinical Markers of Adverse Remodeling for Heart Failure in the Aging Population
B. Jugdutt (2014)
Depressor effect of chymase inhibitor in mice with high salt-induced moderate hypertension.
S. Devarajan (2015)
The controversial role of mast cells in fibrosis
P. Bradding (2018)
Knocking Out Angiotensin II in the Heart
D. Zablocki (2011)
Activation pattern of ACE2/Ang-(1-7) and ACE/Ang II pathway in course of heart failure assessed by multiparametric MRI in vivo in Tgαq*44 mice.
U. Tyrankiewicz (2018)
Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients.
J. Kovarik (2017)
Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-( 1-12) Axis in the Pathogenesis of Diabetic Retinopathy.
M. Ola (2017)
Chapter 15 – Mast Cells
P. Nigrovic (2017)
Critical role of the chymase/angiotensin-(1-12) axis in modulating cardiomyocyte contractility.
Tiankai Li (2018)
Novedades en el sistema renina-angiotensina
F. Serna (2014)
systemic inflammation of alveolar hypoxia MCP-1 initiates the microvascular phase of the Renin released from mast cells activated by circulating
Jie Chao (2011)
RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches
Rukhsana Gul (2012)
The role of immune cells in atrial fibrillation.
Y. Liu (2018)
Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and leucocyte recruitment in vivo.
C. Company (2011)
The year in heart failure.
A. Owens (2011)
Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?
A. Nehme (2017)
Uptake and Metabolism of the Novel Peptide Angiotensin-(1-12) by Neonatal Cardiac Myocytes
S. Ahmad (2011)
CLINICAL IMPLICATIONS OF RENIN-ANGIOTENSIN SYESTEM IN MAMMALS
S. Khalid (2016)
New Take on the Role of Angiotensin II in Cardiac Hypertrophy and Fibrosis
Mazen O. Kurdi (2011)
Deficiency of mouse mast cell protease 4 mitigates cardiac dysfunctions in mice after myocardium infarction.
Yunzhe Wang (2019)
Future drug discovery in renin-angiotensin-aldosterone system intervention
M. Tamargo (2017)
Qiliqiangxin improves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase.
Wei Liu (2012)
Cellular Pathways of Death and Survival in Acute Myocardial Infarction
Wesley T. O'Neal (2013)
A systematic review and meta-analysis
Lin Wang (2012)See more